HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chaiamnuay, S. Articles by Curtis, J. R. Search for Related Content PubMed PubMed Citation Articles by Chaiamnuay, S. Articles by Curtis, J. R.

SUMAPA CHAIAMNUAY, M.D., is Clinical Fellow in Rheumatology, Division of Immunology and Rheumatology, University of Alabama at Birmingham (UAB). JEROAN J. ALLISON, M.D., M.SC., is Associate Professor, Center for Education and Research on Therapeutics of Musculoskeletal Diseases (CERTMD), UAB. JEFFREY R. CURTIS, M.D., M.P.H., is Assistant Professor, Division of Immunology and Rheumatology, and Associate Director, CERTMD, UAB.

Address correspondence to Dr. Curtis at the University of Alabama at Birmingham, Faculty Office Tower 840, 510 20th Street South, Birmingham, AL 35294 (jcurtis{at}uab.edu).

Purpose. A summary of the basic science underlying the current controversies regarding cyclooxygenase-2 (COX-2)-selective nonsteroidal antiinflammatory drugs (NSAIDs), including data on their cardiovascular safety, their gastrointestinal (GI) benefits, cost-effectiveness, physician-prescribing trends, and recommendations for prescribing these agents is presented. Summary. A number of randomized controlled trials (RCTs) have reported that COX-2-selective NSAIDs increase cardiovascular events, although there appear to be gradations of risks among the COX-2-selective NSAIDs. In addition, traditional NSAIDs may increase the risk for cardiovascular events, complicating the interpretation of RCTs that use traditional NSAIDs as comparators. Selective inhibitors of COX-2-selective NSAIDs are effective antiinflammatory and analgesic drugs with improved upper-GI safety compared to traditional NSAIDs. Data on the cost-effectiveness of COX-2-selective NSAIDs indicate that they should be limited to patients at high risk for upper-GI adverse effects. However, they had been increasingly used in patients with lower GI risks until recent events reversed that trend. Circumstances under which COX-2-selective NSAIDs may be appropriate are in patients at high GI risk and in patients who did not respond to multiple traditional NSAIDs. The national spotlight in the United States on NSAID-related adverse events and recent lawsuits against health care providers prescribing COX-2-selective NSAIDs further highlights the need for provider–patient communication and risk disclosure. The relative cardiovascular risks of NSAIDs are similar in magnitude to other currently prescribed therapies. Conclusion. Health care providers must consider the efficacy, GI and cardiovascular risks, concomitant medications, and costs when determining the appropriateness of COX-2-selective NSAID therapy. Index terms: Antiinflammatory agents; Costs; Drug interactions; Drug use; Laws; Patient information; Pharmacoeconomics; Physicians; Prescribing; Rational therapy; Toxicity

 

This article has been cited by other articles:

				C. Y.-C. Peng, D. Sankaran, M. R. Ogborn, and H. M. Aukema Dietary Soy Protein Selectively Reduces Renal Prostanoids and Cyclooxygenases in Polycystic Kidney Disease Experimental Biology and Medicine, July 1, 2009; 234(7): 737 - 743. [Abstract] [Full Text] [PDF]